Literature DB >> 25687798

Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung.

Sameem Abedin1, Gregory A Yanik2, Thomas Braun2, Attaphol Pawarode2, John Magenau2, Steven C Goldstein2, John E Levine2, Carrie L Kitko2, Daniel R Couriel2.   

Abstract

Bronchiolitis obliterans syndrome (BOS) is a significant post-transplant complication with low survival. BOS stage 0p (BOS 0p) is a parameter detected on pulmonary function tests (PFTs) after lung transplantation to identify patients at risk to develop BOS. We performed a retrospective study on 442 patients who underwent allogeneic stem cell transplant from 2007 to 2011 to evaluate whether development of BOS 0p is a risk factor in this population for BOS. Patients who met criteria for BOS 0p were significantly more likely to develop BOS (hazard ratio [HR], 3.22; P < .001). BOS 0p was significantly associated with a history of lung disease pretransplant (HR, 2.48; P = .001) and chronic graft-versus-host disease (GVHD) outside the lung post-transplant (HR, 23; P < .001). Finally, BOS 0p criteria were adequately sensitive in predicting BOS (85%), with a high negative predictive value (98%). Our findings suggest a routine PFT screening strategy with the intent of detecting BOS 0p, especially among patients with prior lung disease and who developed chronic GVHD, could suitably identify an at-risk population for the development of BOS.
Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BOS 0p; Bronchiolitis obliterans syndrome; Chronic GVHD

Mesh:

Substances:

Year:  2015        PMID: 25687798      PMCID: PMC4970454          DOI: 10.1016/j.bbmt.2015.02.006

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  16 in total

1.  Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group.

Authors:  O Ringdén; M Remberger; T Ruutu; J Nikoskelainen; L Volin; L Vindeløv; T Parkkali; S Lenhoff; B Sallerfors; L Mellander; P Ljungman; N Jacobsen
Journal:  Blood       Date:  1999-04-01       Impact factor: 22.113

2.  Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation.

Authors:  Brandon K C Au; Margaret A Au; Jason W Chien
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-30       Impact factor: 5.742

3.  Lung transplantation for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: a single-center experience.

Authors:  Ursula M Vogl; Kazuhiro Nagayama; Marija Bojic; Mir Ali Reza Hoda; Walter Klepetko; Peter Jaksch; Sabine Dekan; Viktoria Siersch; Margit Mitterbauer; Peter Schellongowski; Hildegard T Greinix; Ventzislav Petkov; Axel Schulenburg; Peter Kalhs; Werner Rabitsch
Journal:  Transplantation       Date:  2013-02-27       Impact factor: 4.939

4.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

5.  Diagnosis and staging of chronic graft-versus-host disease in the clinical practice.

Authors:  Hildegard T Greinix; Christoph Loddenkemper; Steven Z Pavletic; Ernst Holler; Gerard Socié; Anita Lawitschka; Joerg Halter; Daniel Wolff
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-05       Impact factor: 5.742

6.  Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation.

Authors:  Jason W Chien; Paul J Martin; Ted A Gooley; Mary E Flowers; Susan R Heckbert; W Garrett Nichols; Joan G Clark
Journal:  Am J Respir Crit Care Med       Date:  2003-03-20       Impact factor: 21.405

7.  Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.

Authors:  Kirsten M Williams; Jason W Chien; Mark T Gladwin; Steven Z Pavletic
Journal:  JAMA       Date:  2009-07-15       Impact factor: 56.272

8.  Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes.

Authors:  Arkadiusz Z Dudek; Hemchandra Mahaseth; Todd E DeFor; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2003-10       Impact factor: 5.742

Review 9.  Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease.

Authors:  Jason W Chien; Steven Duncan; Kirsten M Williams; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2009-11-05       Impact factor: 5.742

10.  Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Authors:  Lee Gazourian; Angela J Rogers; Ruby Ibanga; Gerald L Weinhouse; Victor Pinto-Plata; Jerome Ritz; Robert J Soiffer; Joseph H Antin; George R Washko; Rebecca M Baron; Vincent T Ho
Journal:  Am J Hematol       Date:  2014-02-21       Impact factor: 10.047

View more
  17 in total

Review 1.  How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.

Authors:  Kirsten M Williams
Journal:  Blood       Date:  2016-11-16       Impact factor: 22.113

2.  Spirometry States the Obvious: Recognizing Bronchiolitis Obliterans Syndrome Early after Hematopoietic Cell Transplantation.

Authors:  Elizabeth A Belloli; Vibha N Lama
Journal:  Ann Am Thorac Soc       Date:  2016-11

3.  Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.

Authors:  Anne Bergeron; Sylvie Chevret; Angela Granata; Patrice Chevallier; Laure Vincent; Anne Huynh; Reza Tabrizi; Hélène Labussiere-Wallet; Marc Bernard; Sylvain Chantepie; Jacques-Olivier Bay; Anne Thiebaut-Bertrand; Sylvain Thepot; Nathalie Contentin; Luc-Matthieu Fornecker; Natacha Maillard; Karine Risso; Ana Berceanu; Didier Blaise; Regis Peffault de La Tour; Jason W Chien; Valérie Coiteux; Gérard Socié
Journal:  JAMA       Date:  2017-08-08       Impact factor: 56.272

4.  Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network.

Authors:  John E Levine; Joseph H Antin; Carl E Allen; Lauri M Burroughs; Kenneth R Cooke; Steven Devine; Helen Heslop; Ryotaro Nakamura; Julie An Talano; Gregory Yanik; Nancy DiFronzo
Journal:  Biol Blood Marrow Transplant       Date:  2020-02-05       Impact factor: 5.742

5.  Pulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients.

Authors:  Ajay Sheshadri; Roy F Chemaly; Amin M Alousi; Pankil K Shah; Gabriela Rondon; Lara Bashoura; Joumana Kmeid; Jacques Azzi; David W Blanco; Maryam Kaous; Burton F Dickey; Richard E Champlin; Dimpy P Shah
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-03       Impact factor: 5.742

6.  Noninfectious complications of hematopoietic cell transplantation.

Authors:  Kirsten M Williams
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 7.  Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.

Authors:  Helen E Heslop; Edward A Stadtmauer; John E Levine; Karen K Ballen; Yi-Bin Chen; Amy E DeZern; Mary Eapen; Mehdi Hamadani; Betty K Hamilton; Parameswaran Hari; Richard J Jones; Brent R Logan; Leslie S Kean; Eric S Leifer; Frederick L Locke; Richard T Maziarz; Eneida R Nemecek; Marcelo Pasquini; Rachel Phelan; Marcie L Riches; Bronwen E Shaw; Mark C Walters; Amy Foley; Steven M Devine; Mary M Horowitz
Journal:  Transplant Cell Ther       Date:  2021-08-27

8.  Early Post-Transplantation Spirometry Is Associated with the Development of Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Kareem Jamani; Qianchuan He; Yang Liu; Chris Davis; Jesse Hubbard; Gary Schoch; Stephanie J Lee; Ted Gooley; Mary E D Flowers; Guang-Shing Cheng
Journal:  Biol Blood Marrow Transplant       Date:  2019-12-09       Impact factor: 5.742

9.  Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant.

Authors:  Guang-Shing Cheng; Barry Storer; Jason W Chien; Madan Jagasia; Jesse J Hubbard; Linda Burns; Vincent T Ho; Joseph Pidala; Jeanne Palmer; Laura Johnston; Sebastian Mayer; Kristina Crothers; Iskra Pusic; Stephanie J Lee; Kirsten M Williams
Journal:  Ann Am Thorac Soc       Date:  2016-11

10.  Concurrent Reductions in Spirometry Predict Mortality and Bronchiolitis Obliterans in Chronic Graft-versus-Host Disease.

Authors:  David N O'Dwyer; Yizhuo Wang; Dawson Myers; Bethany B Moore; Susan Murray; Gregory A Yanik
Journal:  Ann Am Thorac Soc       Date:  2021-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.